Literature DB >> 10785590

Experience in qualitative and quantitative FDG PET in follow-up of patients with suspected recurrence from head and neck cancer.

M Lapela1, A Eigtved, S Jyrkkiö, R Grénman, T Kurki, P Lindholm, J Nuutinen, E Sutinen, O Solin, I Bjornskov, P Bretlau, L Friberg, S Holm, M Jensen, H Sand Hansen, H Minn.   

Abstract

We evaluated positron emission tomography (PET) with 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) in the detection of recurrent head and neck cancer, and compared visual and quantitative interpretation of PET images for their accuracy in the identification of tumour recurrence. Sixty-two FDG PET studies were performed in 56 patients having a total of 81 lesions, which were clinically suspected for recurrent carcinoma of the head and neck. The PET images were interpreted visually, and tracer uptake was quantitated as the standardised uptake value adjusted to body weight (SUV). Sensitivity of visual interpretation of the PET images for the presence of malignancy ranged from 84 to 95%, and specificity from 84 to 93%, respectively, depending on the selected scheme for grading of the lesions. Malignant lesions accumulated significantly more FDG than the benign ones (the median SUVs were 6.8 and 3.3, respectively, P<0.001). However, there was a wide overlap of the FDG uptake values between these two groups. Hence, the highest accuracy of quantitative analysis in correct identification of tumour recurrence (75% at Receiver Operating Curve analysis) was inferior to that of visual analysis (89%). FDG PET is feasible for the detection of recurrent head and neck cancer. Although quantitation of FDG uptake using SUV shows significantly higher tracer concentrations for malignant than benign lesions, the wide overlap of individual SUVs between these two groups is a serious concern in diagnostic evaluation. Therefore, in clinical practice it may be preferable to identify the presence of tumour recurrence within this patient group by qualitative interpretation of the PET images.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10785590     DOI: 10.1016/s0959-8049(00)00037-x

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  20 in total

1.  Evaluation of head and neck squamous cell carcinoma after treatment.

Authors:  Suresh K Mukherji; Gregory T Wolf
Journal:  AJNR Am J Neuroradiol       Date:  2003-10       Impact factor: 3.825

Review 2.  The role of FDG PET-CT in the therapeutic evaluation for HNSCC patients.

Authors:  Joji Kawabe; Shigeaki Higashiyama; Atsushi Yoshida; Kohei Kotani; Susumu Shiomi
Journal:  Jpn J Radiol       Date:  2012-04-05       Impact factor: 2.374

3.  Feasibility study of the use of similarity maps in the evaluation of oncological dynamic positron emission tomography images.

Authors:  T Thireou; G Kontaxakis; L G Strauss; A Dimitrakopoulou-Strauss; S Pavlopoulos; A Santos
Journal:  Med Biol Eng Comput       Date:  2005-01       Impact factor: 2.602

4.  Advantages and pitfalls of 18F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting locally residual or recurrent nasopharyngeal carcinoma: comparison with magnetic resonance imaging.

Authors:  Sheng-Chieh Chan; Shu-Hang Ng; Joseph Tung-Chieh Chang; Chien-Yu Lin; Yen-Chao Chen; Yu-Chen Chang; Cheng-Lung Hsu; Hung-Ming Wang; Chun-Ta Liao; Tzu-Chen Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-04-19       Impact factor: 9.236

Review 5.  Functional imaging in head and neck cancer.

Authors:  David I Kutler; Richard J Wong; Dennis H Kraus
Journal:  Curr Oncol Rep       Date:  2005-03       Impact factor: 5.075

6.  Guidelines for the Surgical Management of Laryngeal Cancer: Korean Society of Thyroid-Head and Neck Surgery.

Authors:  Soon-Hyun Ahn; Hyun Jun Hong; Soon Young Kwon; Kee Hwan Kwon; Jong-Lyel Roh; Junsun Ryu; Jun Hee Park; Seung-Kuk Baek; Guk Haeng Lee; Sei Young Lee; Jin Choon Lee; Man Ki Chung; Young Hoon Joo; Yong Bae Ji; Jeong Hun Hah; Minsu Kwon; Young Min Park; Chang Myeon Song; Sung-Chan Shin; Chang Hwan Ryu; Doh Young Lee; Young Chan Lee; Jae Won Chang; Ha Min Jeong; Jae-Keun Cho; Wonjae Cha; Byung Joon Chun; Ik Joon Choi; Hyo Geun Choi; Kang Dae Lee
Journal:  Clin Exp Otorhinolaryngol       Date:  2017-01-03       Impact factor: 3.372

7.  Guidelines for the Surgical Management of Oral Cancer: Korean Society of Thyroid-Head and Neck Surgery.

Authors:  Young-Hoon Joo; Jae-Keun Cho; Bon Seok Koo; Minsu Kwon; Seong Keun Kwon; Soon Young Kwon; Min-Su Kim; Jeong Kyu Kim; Heejin Kim; Innchul Nam; Jong-Lyel Roh; Young Min Park; Il-Seok Park; Jung Je Park; Sung-Chan Shin; Soon-Hyun Ahn; Seongjun Won; Chang Hwan Ryu; Tae Mi Yoon; Giljoon Lee; Doh Young Lee; Myung-Chul Lee; Joon Kyoo Lee; Jin Choon Lee; Jae-Yol Lim; Jae Won Chang; Jeon Yeob Jang; Man Ki Chung; Yuh-Seok Jung; Jae-Gu Cho; Yoon Seok Choi; Jeong-Seok Choi; Guk Haeng Lee; Phil-Sang Chung
Journal:  Clin Exp Otorhinolaryngol       Date:  2019-02-02       Impact factor: 3.372

8.  Diagnostic performance of FDG PET/CT to detect subclinical HNSCC recurrence 6 months after the end of treatment.

Authors:  Philippe Robin; Ronan Abgral; Gérald Valette; Pierre-Yves Le Roux; Nathalie Keromnes; Jean Rousset; Gaël Potard; Xavier Palard; Rémi Marianowski; Pierre-Yves Salaun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-08-29       Impact factor: 9.236

Review 9.  European Laryngological Society: ELS recommendations for the follow-up of patients treated for laryngeal cancer.

Authors:  Ricard Simo; Patrick Bradley; Dominique Chevalier; Frederik Dikkers; Hans Eckel; Nayla Matar; Giorgio Peretti; Cesare Piazza; Mark Remacle; Miquel Quer
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-03-09       Impact factor: 2.503

10.  Usefulness of esophagogastroduodenoscopy and 18F-fluorodeoxyglucose positron-emission tomography in detecting synchronous multiple primary cancers with oral cancer.

Authors:  Naomi Ishibashi-Kanno; Kenji Yamagata; Fumihiko Uchida; Shogo Hasegawa; Toru Yanagawa; Hiroki Bukawa
Journal:  Oral Maxillofac Surg       Date:  2017-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.